Abstract: Disclosed herein are trimeric polypeptide pharmaceutical compositions comprising three monomers, each monomer comprising a polypeptide having the amino acid sequence of the N-terminal heptad repeat (NHR or HR1) or C-terminal heptad repeat (CHR or HR2) of the transmembrane glycoprotein of human immunodeficiency virus (HIV) and a trimerization motif.
Type:
Grant
Filed:
February 8, 2010
Date of Patent:
August 25, 2015
Assignee:
New York Blood Center
Inventors:
Shibo Jiang, Zhi Qi, Xi Chen, Chungen Pan
Abstract: The present invention includes compositions and methods for making and using a vaccine that includes a DC-specific antibody or fragment thereof to which an engineered Gag antigen is attached to form an antibody-antigen complex, wherein the Gag antigen is less susceptible to proteolytic degradation by eliminating one or more proteolytic sites or a DC-specific antibody or fragment thereof to which an engineered Nef antigen is attached to form an antibody-antigen complex, wherein the Nef antigen comprises one or more codon usage optimization that increase antibody-antigen complex secretion, or both, wherein the vaccine is able to elicit an HIV-specific T cell immune response to Gag p17, Gag p24, Nef and/or Cyclin D1.
Type:
Grant
Filed:
July 16, 2009
Date of Patent:
August 18, 2015
Assignee:
Baylor Research Institute
Inventors:
Jacques F. Banchereau, Gerard Zurawski, Anne-Laure Flamar, Amanda Cobb, Holly Mead, Monica Montes, Sandra Zurawski, SangKon Oh
Abstract: We disclose Ebola Sudan Boniface virus GP Monoclonal antibodies, epitopes recognized by these monoclonal antibodies, and the sequences of the variable regions of some of these antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutic treatment of Ebola Sudan Boniface virus infections in vitro and in vivo.
Type:
Grant
Filed:
September 1, 2010
Date of Patent:
August 4, 2015
Assignee:
THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY ON BEHALF OF USAMRMC
Inventors:
John M. Dye, Ana I. Kuehne, Shawn B. Guest
Abstract: Anti-HIV p17 monoclonal antibodies are described, which are capable of neutralizing the binding between multiple HIV-1 p17 protein variants and the p17R receptor are provided. Pharmaceutical compositions and methods of treatment utilizing these antibodies are also provided.
Type:
Grant
Filed:
March 30, 2011
Date of Patent:
July 28, 2015
Assignee:
Medestea Research & Production S.p.A.
Inventors:
Arnaldo Caruso, Giulia Federica Merizzi, Antonio Soleti
Abstract: The present invention provides a recombinant HIV Env antigenic protein, a virus-like particle and a recombinant HIV virus. The present invention further provides a vaccine comprising the recombinant HIV Env antigenic protein, the virus-like particle or recombinant HIV virus.
Abstract: The invention provides a method for obtaining a broadly neutralizing antibody (bNab), including screening memory B cell cultures from a donor PBMC sample for neutralization activity against a plurality of HIV-1 species, cloning a memory B cell that exhibits broad neutralization activity; and rescuing a monoclonal antibody from that memory B cell culture. The resultant monoclonal antibodies are characterized by their ability to selectively bind epitopes from the Env proteins in native or monomeric form, as well as to inhibit infection of HIV-1 species from a plurality of clades. Compositions containing human monoclonal anti-HIV antibodies used for prophylaxis, diagnosis and treatment of HIV infection are provided. Methods for generating such antibodies by immunization using epitopes from conserved regions within the variable loops of gp120 are provided. Immunogens for generating anti-HIV1 bNAbs are also provided. Furthermore, methods for vaccination using suitable epitopes are provided.
Type:
Grant
Filed:
March 17, 2010
Date of Patent:
June 9, 2015
Assignees:
Theraclone Sciences, Inc., International AIDS Vaccine Initiative, The Scripps Research Institute
Inventors:
Po-Ying Chan-Hui, Steven Frey, Ole Olsen, Jennifer Mitcham, Matthew Moyle, Sanjay K. Phogat, Dennis R. Burton, Laura Marjorie Walker, Pascal Raymond Georges Poignard, Wayne Koff, Melissa Danielle De Jean De St. Marcel Simek-Lemos
Abstract: The present invention relates to a viral particle. The viral particle has a radius of less than about 1 ?m, and at least one peptide comprising at least a biologically active portion of CD47. The present invention also includes a method of increasing the life of a particle in vivo in a mammal. The method includes the steps of expressing at least one peptide comprising at least a biologically active portion of CD47 in a viral particle, and administering the viral particle having CD47 expressed to a mammal, wherein the administered viral particle has a longer half life in the mammal than an otherwise identical viral particle that does not have CD47 expressed thereon.
Type:
Grant
Filed:
March 10, 2010
Date of Patent:
June 9, 2015
Assignee:
The Trustees of the University of Pennsylvania
Abstract: The present invention relates, in general, to an immunogenic composition (e.g., a vaccine) and, in particular, to a polyvalent immunogenic composition, such as a polyvalent HIV vaccine containing nucleic acids encoding HIV-1 gag mosaic proteins, and to methods of using same. The invention further relates to methods that use a genetic algorithm to create sets of polyvalent antigens suitable for use, for example, in vaccination strategies.
Type:
Grant
Filed:
August 14, 2009
Date of Patent:
June 2, 2015
Assignees:
LOS ALAMOS NATIONAL SECURITY, LLC, BETH ISRAEL DEACONESS MEDICAL CENTER, DUKE UNIERSITY, THE UAB RESEARCH FOUNDATION
Inventors:
Bette T. Korber, William Fischer, Norman Letvin, Hua-Xin Liao, Barton F. Haynes, Beatrice H. Hahn
Abstract: A sensor chip for detecting an immune response against a virus, the sensor chip including a substrate having a surface and a plurality of virus-like particles or capsid fragments bound to discrete locations on the surface of the substrate. Detection devices containing the sensor chip and methods of detecting anti-viral immune responses are also described herein.
Type:
Grant
Filed:
May 20, 2013
Date of Patent:
May 19, 2015
Assignee:
University of Rochester
Inventors:
Benjamin L. Miller, Tim R. Mosmann, Robert C. Rose, Charles R. Mace
Abstract: The invention is directed to a chimeric gammaretrovirus comprising an gammaretroviral virion which contains a lentiviral Vpx protein and methods of use thereof. In a particular aspect, the chimeric gammaretrovirus is a chimeric murine leukemia virus (MLV) comprising an MLV virion which contains a lentiviral Vpx protein. The invention is also directed to use of the chimeric gammaretrovirus to produce a MLV that can transduce a non-dividing cell (G1/S/G2), transduce a non-dividing cell; enhance the ability of a MLV to transduce a non-dividing cell; transduce a quiescent (G0) cell; and enhance the ability of a human immunodeficiency virus 1 (HIV-1) to transduce a quiescent (G0) cell.
Type:
Grant
Filed:
December 29, 2010
Date of Patent:
May 5, 2015
Assignee:
University of Massachusetts
Inventors:
Mario Stevenson, Rajnish Kaushik, Xiaonan Zhu
Abstract: The present invention relates to nucleic acids encoding mosaic clade M HIV-1 Env polypeptides and to compositions and vectors comprising same. The nucleic acids of the invention are suitable for use in inducing an immune response to HIV-1 in a human.
Type:
Grant
Filed:
April 26, 2011
Date of Patent:
April 21, 2015
Assignees:
Los Alamos National Security, LLC, Duke University, Beth Israel Deaconess Medical Center, The University of Alabama at Birmingham Research Foundation
Inventors:
Bette T. Korber, William Fischer, Hua-Xin Liao, Barton F. Haynes, Norman Letvin, Beatrice H. Hahn
Abstract: The invention is related to a nucleic acid molecule comprising a polynucleotide encoding a modified filovirus glycoprotein (GP) having at least one amino acid change located in a relatively conserved region of said GP that decreases in vitro cytotoxicity and retains immunogenicity when compared to in vitro cytotoxicity and immunogenicity of a wild type filovirus GP, and related modified filovirus GPs, plasmid DNAs, recombinant viruses, adenoviruses, pharmaceutical compositions, vaccine compositions, antibodies that are specifically reactive with the modified filovirus GPs, and related methods of making and using the same.
Type:
Grant
Filed:
January 13, 2012
Date of Patent:
April 21, 2015
Assignee:
The United States of America as Represented by the Secretary of the Department of Health and Human Services
Inventors:
Nancy Sullivan, Bimal Chakrabarti, Zhi-Yong Yang, Maria Grazia Pau, Jaap Goudsmit, Gary Nabel
Abstract: Compounds, compositions and methods for the treatment of HIV/HSP/HPV, in particular, compositions and methods for a 3 part combination therapy for HIV/HSV/HPV, comprising a viral attachment inhibitor, a viral sequence integration inhibitor, and a proviral transcription inhibitor. The therapy is advantageous for the treatment of HIV infection, and is also effective for HSV and HPV infection. Also disclosed are novel viral attachment inhibitors and methods of use.
Type:
Grant
Filed:
January 16, 2008
Date of Patent:
April 14, 2015
Assignee:
The Johns Hopkins University
Inventors:
Ru Chih C. Huang, Ibrahim S. Abd-Elazem
Abstract: The invention relates to a method of preventing or treating acquired immunodeficiency syndrome (AIDS) in a patient, wherein the patient is administered with a Tat protein comprising amino acid sequence SEQ ID NO: 1 or 2, or a variant thereof capable of stimulating an immune response against Tat proteins.
Abstract: This invention relates to compositions and methods for the detection of immunodeficiency virus infection, especially immunodeficiency virus-1 (HIV-I) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies.
Type:
Grant
Filed:
May 21, 2010
Date of Patent:
March 17, 2015
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Abstract: The present invention relates to a method of inducing the production in a patient of anti-HIV antibodies. The method comprises administering to a patient in need thereof an amount of at least one liposome-peptide conjugate in an amount sufficient to effect that induction. The peptide comprises a membrane external proximal region (MPER) epitope and the liposome comprises lysophosphorylcholine or phosphatidylserine.
Type:
Grant
Filed:
April 11, 2008
Date of Patent:
February 17, 2015
Assignee:
Duke University
Inventors:
Barton F. Haynes, S. Munir Alam, Hua-Xin Liao
Abstract: The invention relates to a synthetic gene coding for the Gag protein of the human immunodeficiency virus HIV-1. Said gene may optionally be fused with one or more other HIV sequences. The invention may notably be used within the scope of obtaining anti-HIV vaccines.
Type:
Grant
Filed:
September 10, 2009
Date of Patent:
January 13, 2015
Assignees:
Institut National de la Sante et de la Recherche Medicale, Centre National de la Recherche Scientifique, Universite Paris Est Creteil Val de Marne
Abstract: The instant invention provides TCRs having one or more amino acid substitutions that bind to the AL9 epitope of the HIV protein vpr (AIIRILQQL (SEQ ID NO: 1)).
Type:
Grant
Filed:
March 25, 2010
Date of Patent:
January 13, 2015
Assignee:
Altor BioScience Corporation
Inventors:
Marilyn Fernandez, Bai Liu, Warren D. Marcus, Hing C. Wong
Abstract: This invention provides improved replication-competent adenoviral vectors. The improved vectors have both a hybrid regulatory unit that provides for high level transgene expression. The vectors can be use, e.g., for therapeutic or prophylactic purposes.
Type:
Grant
Filed:
November 17, 2005
Date of Patent:
January 6, 2015
Assignees:
The Government of The United States of America as represented by the Secretary of the Department of Health and Human Services, Istituto Superiore di Sanita
Inventors:
Bo Peng, Rebecca Voltan, Barbara Ensoli, Marjorie Robert-Guroff
Abstract: The present invention provides compositions comprising a vector including a nucleic acid comprising a nucleotide sequence encoding a peptide having the sequence X1LYQYMDDV, wherein X1 is any hydrophobic amino acid. The compositions are used to induce an immune response against human immunodeficiency virus (HIV).
Type:
Grant
Filed:
June 8, 2010
Date of Patent:
November 4, 2014
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services